![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Gilead to Pay Merck $200M in Patent Case
Gilead to Pay Merck $200M in Patent Case
![100Bills_flatmoney.gif](https://www.fdanews.com/ext/resources/test/Drug-Images3/100Bills_flatmoney.gif?t=1578960048&width=430)
A federal jury ruled that Gilead Sciences must dole out $200 million in damages to Merck and Ionis Pharmaceuticals for patent infringement over the active ingredient sofosbuvir in Gilead’s blockbuster hepatitis C drugs.
Merck — which only recently commercialized its own hepatitis C drug Zepatier in 2016 — will continue to seek royalties going forward on licensing rights for use of the patent in a separate case. The $200 million in damages, which was awarded by a jury in the U.S. District Court for the Northern District of California, covers infringement through Dec. 31, 2015.
The ruling was announced March 24 by Merck and followed a decision on March 22 by the same jury that said Sovaldi and Harvoni infringed patents for compounds and methods used to develop medicines based on the nucleotide analog sofosbuvir.
Upcoming Events
-
21Oct